Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail aims to stop Chemo-Induced sickness in stem cell transplants

NCT ID NCT07413809

Symptom relief Sponsor: The Affiliated People's Hospital of Ningbo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding olanzapine to two standard anti-nausea drugs works better than the usual treatment for preventing delayed nausea and vomiting after high-dose chemotherapy. The trial involves 92 multiple myeloma patients undergoing autologous stem cell transplant. Researchers will compare how many patients have no vomiting and need no rescue medication in the days after chemo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fosaprepitant, tropisetron, olanzapine, and dexamethasone
What this could lead to
If successful, this could offer a better way to prevent severe nausea and vomiting after high-dose chemotherapy, improving comfort during stem cell transplant.
What could go wrong
This is a relatively small trial (92 people) and only tests one specific chemo regimen. The new combo may not work better than the standard, and olanzapine can cause side effects like drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 92 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with multiple myeloma who are indicated for autologous hematopoietic stem cell transplantation; * Preconditioning regimen consists of melphalan at a dose of 200 mg/m²; * ECOG performance status score of 0 to 2; * Age \>18 years and \<65 years; * Expected survival time \>3 months; * Absence of intracranial hypertension, gastrointestinal obstruction, or other causes of refractory vomiting; * Ability to understand and provide written informed consent. Exclusion Criteria: * Presence of nausea or vomiting within 48 hours prior to enrollment, with prior use of antiemetic medications; * Current use or use within the past month of CYP3A4 inducers, inhibitors, or substrate drugs; * History of hypersensitivity to fosaprepitant or olanzapine; * Serum creatinine clearance \<60 mL/min; * Inability to receive treatment and follow-up at the designated study site, or inability to comprehend, comply with the study protocol, or provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Affiliated People's Hospital of Ningbo University

    RECRUITING

    Ningbo, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.